StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
086450.KQ$19220.00-2.29%
Fair $19220.00+0.0%

086450.KQ

DongKook Pharmaceutical Co., Ltd.

Unknown / UnknownKOSDAQ

$19220.00

-450.00 (-2.29%)

Fairly Valued+0.0%Fair Value $19220.00Fund rank 28/100 · Data gapFallback financials|
SA 46/C
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 21%

FCF escenarios

weak_data · normalized FCF $22.8B · quality 47.0/100

Data gap 28/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 23/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

46/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 086450.KQLocal privado en este navegador · DongKook Pharmaceutical Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$853.2B

P/E

13.0x

↑

EV/EBITDA

7.0x

↓

ROE

9.9%

↑

Gross Margin

54.1%

↑

Debt/Equity

0.11

↓
52-Week Range$19220
$16260$31250

TradingView lightweight chart

086450.KQ price, volumen y niveles de valoración

Último $19,220Periodo +288.0%
Fair value: $19,220

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+11.9%

FCF CAGR

—

FCF margin

2.5%

FCF / Net income

0.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $926.88B · net income $66.02B · FCF $22.76B

2022-FY → 2025-FY

Gross margin

54.1%-3.3% pts

Operating margin

10.4%-0.8% pts

Net margin

7.1%-0.9% pts

FCF margin

2.5%+4.0% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$926.88B$926.88B$812.17B$730.99B$661.65B
Net Income$66.02B$66.02B$61.22B$47.18B$52.90B
EBITDA$126.38B$126.38B$117.70B$87.80B$92.14B
EPS1475.001475.001368.001055.001183.00
Gross Margin54.1%54.1%55.1%56.2%57.4%
Operating Margin10.4%10.4%9.9%9.1%11.2%
Net Margin7.1%7.1%7.5%6.5%8.0%
Balance Sheet
Debt/Equity0.110.110.130.140.13
Cash Flow
Free Cash Flow$22.76B$22.76B$45.29B$2.44B$-10.32B
Returns
ROE9.9%9.9%10.1%8.7%10.5%
Valuation
P/E13.0313.0311.9215.9113.57
EV/EBITDA6.976.976.468.737.71
P/B1.301.301.211.381.43
Growth & Yield
Revenue Growth14.1%14.1%11.1%10.5%—
EPS Growth7.8%7.8%29.7%-10.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

5.0%

fácil

EPS terminal req.

$1705.45

Spread vs growth

2.9%

5Y implied EPS CAGR

6.9%

razonable

EPS terminal req.

$2063.60

Spread vs growth

0.9%

10Y implied EPS CAGR

8.5%

razonable

EPS terminal req.

$3323.45

Spread vs growth

-0.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +15.5%

Total return

+15.5%

Start / end P/E

12.2x → 13.0x

EPS bridge

1368.00 → 1475.00

Residual

+0.6%

EPS growth+7.8%
Multiple rerating+7.1%
Dividend+0.0%
Residual / FX / buybacks / cross-term+0.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.